- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02174978
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
October 11, 2017 updated by: U.S. Army Medical Research and Development Command
Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) Open-label Dose Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults
The proposed study is a Phase 1 study with controlled human malaria infection (CHMI) designed primarily to evaluate the safety of the FMP012 combined with AS01B adjuvant system.
AS01B is a proprietary current good manufacturing practices (cGMP) grade adjuvant manufactured by GlaxoSmithKline (GSK) Biologicals.
It is a formulation based on liposomes mixed with the immunostimulants monophosphoryl lipid (MPL) and Quillaja saponaria (QS)-21.
The immunogenicity and efficacy of this new candidate vaccine will be evaluated in addition to safety.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Clinical Trials Center, WRAIR
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adults (male or non-pregnant, non-lactating female) 18 to 50 years of age (inclusive) at the time of screening
If the subject is female,
- Non-childbearing potential (ie, either surgically sterilized or one year post-menopausal), abstinent or using adequate contraceptive precautions (eg, intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) during this study and must agree to continue such precautions until three months after challenge
- A negative pregnancy test at the time of enrollment
- Free of significant health problems as established by medical history, laboratory, and clinical examination before entering the study
- Subjects must have low cardiac risk factors according to the National Health and Nutrition Examination Survey (NHANES) I criteria, medical history and family history, blood pressure measurements, and a normal or normal variant ECG
- Available to participate and reachable by phone for duration of study (approximately 8-14 months) and reachable by phone at the 6 month post Controlled Human Malaria Infection (CMHI) follow-up
- No plans to travel to outside the Washington DC area between the day of challenge and either completion of treatment course (post-challenge) or, if subject remains uninfected, 28 days post-challenge
- No plans to travel to a malaria endemic area during the course of the study
- Written informed consent must be obtained from the subject before screening procedures are performed
- Subjects must score at least 80% correct on a multiple-choice quiz that assesses their understanding of this study
- If a subject is active duty military, he or she must obtain approval from his or her supervisor per Walter Reed Army Institute of Rese (WRAIR) Policy 11-45
Exclusion Criteria:
- Any history of malaria infection
- History of travel to P falciparum endemic areas in the 3 months prior to day of first vaccination (Vaccination Groups) or day of challenge (Infectivity Control Group)
- Any history of receiving a malaria vaccine
- Receipt of any licensed vaccine within 7 days prior to first vaccination (Note: subjects are encouraged to get recommended licensed preventive vaccinations during the course of the study but are requested to schedule any routine preventive vaccinations for at least 7 days before or after a scheduled FMP012/AS01B vaccination day)
- History of receipt of malaria prophylaxis during the 2 months prior to day of first vaccination (Vaccination Groups) or day of challenge (Infectivity Control Group)
- History of use of any antibiotics with significant antimalarial activity (examples include tetracycline, doxycycline, clindamycin, azithromycin, and sulfa drugs) during the course of the study period (period starting one month prior to challenge, Infectivity Control Group)
- Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine or planned use during the study period.
- Any history of allergic reaction or anaphylaxis to previous vaccination (Vaccination Groups)
- Allergy to egg protein (Vaccination Groups)
- Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at screening or plans to become pregnant or breastfeed from the time of enrollment until three months after challenge
- Allergy to antimalarial drugs or use of medications known to interact with chloroquine (CQ)
- Significant (eg, systemic) hypersensitivity reactions to mosquito bites (local hypersensitivity reactions at the site of mosquito bites are not an exclusion criterion)
- History of sickle cell disease
- History of psoriasis or porphyria
- History of splenectomy
- Any confirmed or suspected immunodeficiency, including HIV infection
- Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune-modifying drugs within 6 months of vaccination
- History of autoimmune disease
- Family history of congenital or hereditary immunodeficiency
- Acute or chronic, clinically significant, pulmonary, cardiovascular, endocrine, hepatic, or renal functional abnormality, as determined by history, physical examination, or laboratory evaluation
- Chronic or active neurologic disease including seizure disorder and chronic migraine headaches
- Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or any planned administration during the study period
Any abnormal baseline laboratory screening tests to include:
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above normal range,
- Creatinine above normal range,
- Hemoglobin out of normal range,
- Platelet count out of normal range, or
- Total white blood cell (WBC) count out of normal range
- Seropositive for HIV or Hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg) positive
- Hepatomegaly, right upper quadrant abdominal pain or tenderness
- An abnormal baseline screening ECG suggestive of cardiac disease as determined by a clinical investigator
- Suspected or known current alcohol or drug abuse as determined from the medical history or by physical examination
- Any other significant finding that in the opinion of the PI would increase the risk of having an adverse outcome from participating in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1: 10 µg FMP012 adjuvanted AS01B
FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume.
Doses administered intramuscular at week 0, 4, 8, and 24.
On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
|
Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
Other Names:
|
Experimental: Group 2: 30 µg FMP012 adjuvanted AS01B
FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24.
On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
|
Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
Other Names:
|
Other: Infectivity control
Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of solicited adverse events (AE)
Time Frame: 7 days after each vaccination
|
7 days after each vaccination
|
Number of unsolicited AEs
Time Frame: 28 days after each vaccination
|
28 days after each vaccination
|
Occurrence of serious adverse events (SAE) at any time during the study period (enrollment to final follow-up visit)
Time Frame: 12 months after vaccination
|
12 months after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anti-FMP012 antibody titers in serum
Time Frame: 12 months
|
12 months
|
Time to parasitemia by blood smear after the P falciparum challenge
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Jason W Bennett, LTC, MC, Malaria Vaccine Branch, Military Malaria Research Program, WRAIR
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2014
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
June 11, 2014
First Submitted That Met QC Criteria
June 24, 2014
First Posted (Estimate)
June 26, 2014
Study Record Updates
Last Update Posted (Actual)
October 13, 2017
Last Update Submitted That Met QC Criteria
October 11, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-14-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on FMP012 with AS01B adjuvant system
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)Completed
-
U.S. Army Medical Research and Development CommandGlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR); The PATH Malaria...CompletedPlasmodium Falciparum MalariaUnited States
-
U.S. Army Medical Research and Development CommandUnited States Agency for International Development (USAID); IDRICompleted
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsJapan
-
Phytopharm Consulting BrazilLaboratório Saúde Ltda - principal e único patrocinadorUnknown
-
GlaxoSmithKlineCompleted
-
Novartis VaccinesCompleted
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsUnited States, Belgium
-
Sun Yat-sen UniversityUnknown
-
GlaxoSmithKlineActive, not recruitingHerpes SimplexGermany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia